Imagabalin (INN, USAN; PD-332,334) is a drug which acts as a ligand for the α2δ subunit of the voltage-dependent calcium channel, with some selectivity for the α2δ1 subunit over α2δ2. Under development by Pfizer as a pharmaceutical medication , it has demonstrated preclinical efficacy of anxiolytic, analgesic, hypnotic, and anticonvulsant-like activity and is currently in phase III clinical trials for the treatment of generalized anxiety disorder  .
Imagabalin (INN, USAN; PD-0332334) was an investigational drug that acted as a ligand for the α2δ subunit of the voltage-dependent calcium channel, with some selectivity for the α2δ1 subunit over α2δ2. It was under development by Pfizer as a pharmaceutical medication due to its hypothesized anxiolytic, analgesic, hypnotic, and anticonvulsant-like activity . It reached phase-III clinical trials for treatment of generalized anxiety disorder ; however, the trials were terminated by the manufacturer. The drug is no longer under development .
R
PD-332,334) is a drug which acts
PD-0332334) was an investigational drug that acted
R
Under
It was under
R
, it has demonstrated preclinical efficacy of
due to its hypothesized
R
and is currently in phase III
. It reached phase-III
D
the
A
; however, the trials were terminated by the manufacturer. The drug is no longer under development